2007
Cost-Benefit Analysis of Second-Generation Antipsychotics and Placebo in a Randomized Trial of the Treatment of Psychosis and Aggression in Alzheimer Disease
Rosenheck RA, Leslie DL, Sindelar JL, Miller EA, Tariot PN, Dagerman KS, Davis SM, Lebowitz BD, Rabins P, Hsiao JK, Lieberman JA, Schneider LS. Cost-Benefit Analysis of Second-Generation Antipsychotics and Placebo in a Randomized Trial of the Treatment of Psychosis and Aggression in Alzheimer Disease. JAMA Psychiatry 2007, 64: 1259-1268. PMID: 17984395, DOI: 10.1001/archpsyc.64.11.1259.Peer-Reviewed Original ResearchConceptsCost-benefit analysisSecond-generation antipsychoticsGreatest net health benefitNet benefit analysisNet health benefitWholesale priceHealth Utilities Index Mark 3Economic perspectiveAlzheimer's diseaseBenefit approachHealth care costsTotal health costsHealth costsQALYsCare costsMeasures of effectivenessPlacebo-controlled trialLower health care costsHealth service useTotal health careMeasures of functionCostTreatment of psychosisQuality of lifeSensitivity analysis
2001
Naltrexone in the Treatment of Alcohol Dependence
Krystal J, Cramer J, Krol W, Kirk G, Rosenheck R. Naltrexone in the Treatment of Alcohol Dependence. New England Journal Of Medicine 2001, 345: 1734-1739. PMID: 11742047, DOI: 10.1056/nejmoa011127.Peer-Reviewed Original ResearchConceptsMonths of placeboSevere alcohol dependenceAlcohol dependencePlacebo-controlled evaluationUse of naltrexoneOpiate receptor antagonistTreatment of menSignificant differencesPercentage of daysStudy medicationNaltrexone groupPlacebo groupNumber of drinksAlcoholics Anonymous meetingsPsychosocial treatmentsNaltrexoneDrug AdministrationPatientsMonthsIndividual counselingNumber of daysPlaceboTreatmentWeeksDaysDetecting Improvement in Quality of Life and Symptomatology in Schizophrenia
Cramer J, Rosenheck R, Xu W, Henderson W, Thomas J, Charney D, Schizophrenia D. Detecting Improvement in Quality of Life and Symptomatology in Schizophrenia. Schizophrenia Bulletin 2001, 27: 227-234. PMID: 11354590, DOI: 10.1093/oxfordjournals.schbul.a006869.Peer-Reviewed Original Research
1999
Impact of Clozapine on Negative Symptoms and on the Deficit Syndrome in Refractory Schizophrenia
Rosenheck R, Dunn L, Peszke M, Cramer J, Xu W, Thomas J, Charney D, Schizophrenia T. Impact of Clozapine on Negative Symptoms and on the Deficit Syndrome in Refractory Schizophrenia. American Journal Of Psychiatry 1999, 156: 88-93. PMID: 9892302, DOI: 10.1176/ajp.156.1.88.Peer-Reviewed Original ResearchConceptsRefractory schizophreniaDeficit syndromeNegative symptomsPositive symptomsClozapine's effectVeterans Administration TrialEffects of clozapineImpact of clozapineNegative clinical symptomsProminent negative symptomsClozapine treatmentHospitalized patientsConventional medicationsClinical symptomsControl subjectsAdministration trialClinical subtypesAnalysis of covariancePatientsClozapineSyndromeSymptomsNegative syndromeSchizophreniaTime points
1998
Multiple outcome assessment in a study of the cost-effectiveness of clozapine in the treatment of refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.
Rosenheck R, Cramer J, Xu W, Grabowski J, Douyon R, Thomas J, Henderson W, Charney D. Multiple outcome assessment in a study of the cost-effectiveness of clozapine in the treatment of refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. Health Services Research 1998, 33: 1237-61. PMID: 9865219, PMCID: PMC1070315.Peer-Reviewed Original ResearchConceptsCost-effectiveness ratioRefractory schizophreniaVeterans Affairs Cooperative Study GroupHigh hospital usersIncremental cost-effectiveness ratioDouble-blind trialCooperative Study GroupDisease-specific measuresVA Medical CenterStandard assessment instrumentsMeasures of symptomsMultiple outcome domainsQuality Adjusted Life YearsComposite health indexAdjusted Life YearsHealth indexStudy entryPercent confidence intervalsAverage annual costStandard treatmentCost dataRole functioningStudy groupMedical CenterSide effectsPredictors of differential response to clozapine and haloperidol
Rosenheck R, Lawson W, Crayton J, Cramer J, Xu W, Thomas J, Stolar M, Charney D, Schizophrenia F. Predictors of differential response to clozapine and haloperidol. Biological Psychiatry 1998, 44: 475-482. PMID: 9777179, DOI: 10.1016/s0006-3223(98)00117-6.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAntipsychotic AgentsClozapineDouble-Blind MethodDrug ResistanceFemaleHaloperidolHumansMalePsychiatric Status Rating ScalesQuality of LifeRacial GroupsSchizophreniaSchizophrenic PsychologySocial SupportTreatment OutcomeUnited StatesUnited States Department of Veterans AffairsConceptsQuality of lifeThree-month outcomeOnset of schizophreniaSeverity of symptomsGreater symptom reductionGreater improvementRefractory patientsRefractory schizophreniaClozapine treatmentHospital daysClinical predictorsExtrapyramidal symptomsHospitalized patientsClinical trialsBaseline predictorsSample patientsSide effectsSymptom reductionClozapinePatientsSymptomsHigher symptomsHigh levelsHaloperidolMultiple regression analysis
1997
A Comparison of Clozapine and Haloperidol in Hospitalized Patients with Refractory Schizophrenia
Rosenheck R, Cramer J, Xu W, Thomas J, Henderson W, Frisman L, Fye C, Charney D. A Comparison of Clozapine and Haloperidol in Hospitalized Patients with Refractory Schizophrenia. New England Journal Of Medicine 1997, 337: 809-815. PMID: 9295240, DOI: 10.1056/nejm199709183371202.Peer-Reviewed Original ResearchConceptsClozapine groupExtrapyramidal side effectsHaloperidol groupRefractory schizophreniaSide effectsAntipsychotic drugsDouble-blind comparative studyVeterans Affairs Medical CenterMore outpatient servicesNegative Syndrome ScaleComparison of clozapineLower symptom levelsSimilar overall costsHospitalized patientsTreat analysisTardive dyskinesiaPsychiatric reasonsLower incidenceMedical CenterOutpatient servicesHospital usePatientsSyndrome ScaleClozapineHaloperidol